Excelimmune, a Woburn, MA-based developer of drugs made with human recombinant polyclonal antibodies, has raised $4.5 million of a planned $9 million round of equity financing, according to an SEC filing. The document did not specify the investors in the deal. The company, founded in 2006, took in $1 million in Series B funding in February to advance development of Staphguard, an experimental drug for staph infections that are immune to the antibiotic methicillin.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
